1 |
Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015;132(17):1667-78.
DOI
|
2 |
de Fatima Marinho de Souza M, Gawryszewski VP, Ordunez P, Sanhueza A, Espinal MA. Cardiovascular disease mortality in the americas: Current trends and disparities. Heart 2012;98(16):1207-12.
DOI
|
3 |
Jee SH, Jang Y, Oh DJ, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ open 2014;4(5):e005025.
DOI
|
4 |
Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: A systematic review. JAMA 2005;294(17):2203-9.
DOI
|
5 |
Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US preventive services task force. JAMA 2016;316(19):2008-2024.
DOI
|
6 |
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292(5519):1160-4.
DOI
|
7 |
Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92(2):152-60.
DOI
|
8 |
Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81(5):582-7.
DOI
|
9 |
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract 2018;24(1):91-120.
DOI
|
10 |
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: A report from the american heart association. Circulation 2019;139(10):e56-e528.
|
11 |
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333(20):1301-1307.
DOI
|
12 |
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111-88.
DOI
|
13 |
Son KB, Bae S. Patterns of statin utilisation for new users and market dynamics in South Korea: A 13-year retrospective cohort study. BMJ open 2019;9(3):e026603.
DOI
|
14 |
Naito R, Miyauchi K, Daida H. Racial differences in the cholesterollowering effect of statin. J Atheroscler Thromb 2017;24(1):19-25.
DOI
|
15 |
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37(39):2999-3058.
DOI
|
16 |
Kim S, Han S, Rane PP, Qian Y, Zhao Z, Suh HS. Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea. PLoS One 2020;15(1):e0228472.
DOI
|
17 |
Kwon JE, Kim Y, Hyun S, et al. Cholesterol lowering effects of low-dose statins in Korean patients. J lipid Atheroscler 2014;3(1):21-28.
DOI
|
18 |
Korea Centers for Disease Control & Prevention. Chronic disease status and issues 2019. Available from:http://nih.go.kr/gallery.es?mid=a20503020000&bid=0003&b_list=9&act=view&list_no=144581&nPage=1&vlist_no_npage=2&keyField=&keyWord=&orderby=. Accessed May 01, 2021.
|
19 |
Kim HJ, Kim Y, Cho Y, Jun B, Oh KW. Trends in the prevalence of major cardiovascular disease risk factors among Korean adults: Results from the Korea National Health and Nutrition Examination Survey, 1998-2012. Int J Cardiol 2014;174(1):64-72.
DOI
|
20 |
Rhee E, Kim HC, Kim JH, et al. 2018 guidelines for the management of dyslipidemia in Korea. Journal of Lipid and Atherosclerosis. 2019;8(2):78-131.
DOI
|